Agenda
|
Session I. Critical Considerations for Lead Optimization
|
Thursday, June 22, 2023
1 pm – 2:30 pm |
|---|---|
| Overview of lead optimization | Steven Olson, Ph.D., Executive Director, Medicinal Chemistry, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute |
| ADMET assessment | Li Di, Ph.D., Research Fellow, Dynamics, and Metabolism Department, Pfizer |
|
Session II. Considerations for Advancing to Late Preclinical Development
|
Friday, June 23, 2023
1 pm – 2:30 pm |
| Criteria for an SM entering IND-enabling studies | Li Di, Ph.D., Research Fellow, Dynamics, and Metabolism Department, Pfizer Elizabeth Glaze, Ph.D., Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute |
| Development of pharmacodynamic biomarkers | Apurva Srivastava, Ph.D., DABCC, Senior Principal Scientist at Leidos Biomedical Research, INC. |
|
Session III. Safety and Toxicity Studies for Small Molecules
|
Thursday, July 13, 2023
1 pm – 2 pm |
| Safety and toxicity studies for small molecules | Elizabeth Glaze, Ph.D., Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute |
|
Session IV. Formulation of Small Molecules
|
Friday, July 14, 2023
1 pm – 2:30 pm |
| Formulation considerations during lead optimization | Huan Xie, Ph.D., Professor, Department of Pharmaceutical Science, Texas Southern University |
| Formulation studies for clinical candidates | Jing Ling, Ph.D., Associate Principle Scientist, Discovery Pharmaceutical Sciences, Merck |
|
Session V. Nanoparticle Delivery of Cancer Drugs
|
Thursday, July 27, 2023
1 pm – 2:30 pm |
| Overview and nanoparticle characterization | Stephan Stern, Ph.D., DABT Laboratory Co-Director, Director of Research and Development, and Head of the pharmacology and toxicology section of the Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research |
| FDA regulatory considerations for nanomedicines | Wimolnut Manheng, Ph.D., DABT, Toxicologist, Center for Drug Evaluation and Research, Food and Drug Administration |
|
Session VI: Good-to-know IP Knowledge
|
Friday, July 28, 2023
1 pm – 2 pm |
| Good-to-know IP Knowledge | Jason Cristofaro, Ph.D., J.D., Intellectual Property Program Manager, Division of Cancer Treatment and Diagnosis, National Cancer Institute |